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Dear Editor,
Recently, Ding et al. [1] reported that 
administration of glycyrrhizin (50 mg/kg/
day), a glycoconjugated triterpene pro-
duced by the licorice plant Glycyrrhiza gla-
bra, reduced high-fat diet-induced athero-
sclerosis in Apoe–/– mice by significantly 
decreasing serum high-mobility group box 
protein 1 (HMGB1) and lipid levels and by 
increasing the Treg/Th17 ratio.
Several natural compounds, such as 
krill oil, vitamin D, and dipotassium glyc-
yrrhizate (DPG), a salt of glycyrrhizin, have 
been extensively investigated in our labora-
tory as therapeutic options for the treat-
ment of intestinal inflammation, showing 
reliable anti-inflammatory properties [2–
4]. Currently, atherosclerosis is thought as 
a chronic disease in which systemic inflam-
mation underlies the accumulation of 
plaques in the arterial intima. Thus, we also 
considered intriguing possibility to use 
DPG, a natural compound with known an-
ti-inflammatory properties and scarce or 
negligible side effects [5], as a good strategy 
to reduce atherosclerotic lesions.
Cardiovascular disease (CVD) remains 
the most common cause of death in both 
males and females; however, in the last de-
cades, female CVD deaths exceeded those 
of males [6–8]. Furthermore, most of the 
risk factors for CVD (hypertension, high 
blood cholesterol level, lack of physical ac-
tivity, and obesity) are similar for males and 
females, but smoking has a greater negative 
effect in females [9]. Notably, the influence 
of gender on atherosclerosis development 
has also been described in animal models. 
Indeed, female ApoE−/− mice develop sig-
nificantly increased aortic atherosclerotic 
lesion and intima/media thickness com-
pared to male mice [10]. Despite these find-
ings, most in vivo studies have been carried 
out on males. To overcome this gap, here, 
we used female ApoE−/− mice.
For our purposes, 14 week-old ApoE−/− 
female mice (n = 8/group), fed a standard 
diet, were treated daily with 8 mg/kg/day 
DPG or vehicle by oral gavage for 100 days 
(approx. 14 weeks). Since effects on blood 
pressure, mediated by cortisol accumula-
tion [11], have previously been attributed 
to DPG [12], the cortisol level was monthly 
analyzed by ELISA (MyBiosource, San Di-
ego, CA, USA) in the total serum. Serum 
cholesterol, low-density lipoprotein (LDL), 
and high-density lipoprotein (HDL) con-
centrations were also evaluated at the same 
time points by Mouse Cholesterol ELISA 
Kit (MyBioSource and EMELCA Biosci-
ence, Breda, The Netherlands) and by 
HDK and LDL/VLDL Quantitation Kit 
(Sigma-Aldrich), respectively. At the end 
of treatment, hearts and descending tho-
racic aortas (DTA) were collected and ana-
lyzed as described in our previous work 
[13]. Specifically, DTA (n = 8/group) were 
cut longitudinally, pinned en face, and 
stained with Oil Red O stain. Plaque den-
sity (number of plaques/mm2) was quanti-
fied on digital images of the aorta (from the 
aortic arch down to the diaphragm) cap-
tured with a Leica digital camera and ana-
lyzed by the software NIS-Elements 
BR4.00.05 (Nikon Instruments S.p.A., 
Florence, Italy). Heart sections were cut in 
a plane perpendicular to the aorta axis and, 
once the aortic root was identified by the 
appearance of aortic valve leaflets, serial 
sections were collected and stained with 
Masson’s trichrome or underwent mor-
phometric analyses and immunohisto-
chemistry to assess CD68 and α-SMA ex-
pression.
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Macroscopically, we did not observe 
any heart changes (i.e., cardiac hypertro-
phy) in DPG-treated ApoE−/− mice com-
pared with controls. In support of our 
 results, other authors reported that in 
ApoE−/− mice, heart changes were related 
to and/or aggravated by aging and West-
ern diet [14]. Our results showed that the 
cortisol level is not modulated by DPG 
treatment (serum cortisol: matched con-
trols [CN]: 12.37 ng/mL ± 1.86; DPG 12.70 
ng/mL ± 0.59, p = 0.25; Fig. 1a), suggesting 
that at this concentration, DPG does not 
raise blood pressure, an important side ef-
fect of licorice consumption. Furthermore, 
DPG-treated mice showed significantly re-
duced levels of serum cholesterol and 
LDL compared with the age-matched con-
trol group (serum cholesterol: CN: 13.96 
mmol/L ± 0.45; DPG 10.50 mmol/L ± 0.42, 
p < 0.001; serum LDL: CN: 3.76 mmol/L ± 
0,06; DPG 2.24 mmol/L ± 0.56, p < 0.05; 
Fig.  1b). No change in HDL concentra-
tion was observed after DPG treatment 
(Fig. 1b). 
The density of the atherosclerotic lesion 
(number of plaques/mm2) in the DTA re-
gion was not significantly affected by DPG 
treatment in our experimental conditions 
(Fig.  2a, b). Conversely, cross-sectional 
analysis of the aortic root clearly demon-
strated that DPG treatment induced a de-
crease in the plaque area, approaching bor-
derline statistical significance (Fig.  2c–e). 
Together with the decreased size, DPG-
treated mice showed plaques with a statisti-
cally significant lower necrotic core, one of 
the defining characteristics of a vulnerable 
plaque, compared with control mice 
(Fig.  2f). The more vulnerable status of 
plaques in untreated mice is consistent 
with the higher percentage of foam cells 
(CD68+; Fig. 2g) and smooth muscle cells 
(α-SMA+; Fig. 2i) migrating into the plaque 
from the underlying media compared with 
plaques from DPG-treated mice (Fig. 2h, j).
HMGB1, a known inflammatory medi-
ator, is overexpressed in atherosclerotic le-
sions and exerts proatherogenic effects by 
stimulating macrophage migration, induc-
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Fig. 1. Effect of DPG on serum cortisol and cholesterol levels in 
female ApoE−/− mice and age-matched controls (CN) 14 weeks 
after treatment. Serum cortisol (a), cholesterol, LDL, and HDL 
concentrations (b) were analyzed by ELISA. Data are reported as 
mean ± SEM. Differences were tested with Student’s t test. *** p < 
0.001, * p < 0.05. The concentration of cortisol is given as ng/mL. 
For cholesterol determination, murine sera were diluted (1: 5), and 
the concentration is given as mmol/L. For cortisol and cholesterol, 
ELISA changes in the optical density were measured at 450 nm; for 
LDL and HDL, the concentration is given as mmol/L, and changes 
in the optical density were measured at 560 nm. Each sample (8 
samples per group) was analyzed in duplicate.
Fig. 2. Effects of DPG on atherosclerosis. 
Representative en face preparations of 
DTA and aortic root sections from female 
ApoE−/− mice 14 weeks after treatment 
with 8 mg/kg/day DPG or from age-
matched controls. Plaque density in the 
DTA: representative images (a) and histo-
gram (b) of all samples analyzed (n = 8/
group). Aortic root sections (Masson’s tri-
chrome stain) from CN (c) and DPG-treat-
ed mice (d). Graphic representation of the 
plaque area (e) and necrotic core (f) mea-
sured on aortic root cross-sections of all 
samples analyzed (n = 8/group). Sections of 
atherosclerotic plaques immunostained 
with antibodies against CD68 (g, h) and 
α-SMA (i, j) from CN- and DPG-treated 
mice. Data are shown as mean ± SEM. Dif-
ferences were tested with Student’s t test. 
* p = 0.0168.
(For figure see next page.)
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ing proinflammatory cytokines and pro-
moting the accumulation of immune and 
smooth muscle cells [15]. Thus, the selec-
tively targeting of HMGB1 by DPG, a small 
inhibitor of HMGB1 [16], could decrease 
HMGB1-mediated local inflammation, 
 inducing improvement in atherosclerotic 
plaque progression.
Although our data are in agreement 
with those reported by Ding et al. [1] re-
garding the beneficial effect of licorice on 
the atherosclerosis progression, important 
additional information can be extrapolated 
from our study. Indeed, in agreement with 
the current evidence of a progressive in-
crease in atherosclerosis incidence among 
female, our study was carried out in female 
mice, during standard diet and using a 
5-fold lower concentration of DPG com-
pared to the study by Ding et al. [1].
In conclusion, our study highlights that 
a low dosage of DPG counteracts ath-
erosclerosis progression occurring during 
standard diet. This finding opens the pos-
sibility to propose DPG administration in 
combination with balanced diet to pre-
disposed individuals without the concern 
about the rise in blood pressure, an impor-
tant parameter to be considered with high-
er doses.
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